Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted therapy in severe PTSD
NCT03282123Phase 2Completed
- Sponsor
- Lykos Therapeutics
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Started Nov 2017; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03282123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282123.